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Abstract This was an international survey undertaken to
assess cervical dystonia (CD) patients own perceptions of
their illness and its management. A total of 1,071 self-
identified respondents with CD in 38 countries completed
the online survey between March and December 2012. The
mean time since diagnosis was 9.6 years and over half
(54 %) of patients surveyed were not diagnosed in the first
year. When asked how the symptoms of CD affected them,
two-thirds (66 %) of patients reported they experienced a
lot of pain, and 61 % said that they suffered depression and
mood alterations; only 7 % reported no impact on their
lives. Despite problems with the diagnosis, almost 70 % of
respondents reported being satisfied with the overall rela-
tionship with their doctor. Patient treatment expectations
were high, with 63 % expecting freedom from spasms and
62 % expecting freedom from pain. Over half (53 %)
expected to be able to return to a normal routine (53 %).
The most common treatment reported was botulinum toxin
(BoNT) (86 %), followed by oral medication (58 %) and
physiotherapy/physical therapy (37 %). Among patients
treated on BoNT, 56 % were fairly/very satisfied, 25 %
were fairly/very dissatisfied and 20 % were neither satis-
fied nor dissatisfied with the outcome. In conclusion, this
international survey highlights the broad impact of CD on
several aspects of patient life. Taken overall, the survey
suggests that that patients need to be better informed about
their condition, treatments available and the limitations of
those treatments. It may be that realistically managing
patient expectations of treatment would reduce the dissat-
isfaction of some patients.
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Introduction
Cervical dystonia (CD) is a chronic neurologic condition
primarily characterized by the twisting or turning of the
neck, and/or displacement of the head. Disability with
functional impairment, pain and embarrassment with social
withdrawal are also frequent features of the disorder and
several studies have shown that CD can have important
impact on the patient quality of life [1–3]. The average age
of CD onset is around 41 years [4, 5]; consequently, many
patients are working and have young families when they
are diagnosed [6]. The impact on daily life is significant
and it has been reported that people with CD retire at least
10 years earlier than the general population due to their
condition [7].
Current treatment guidelines recommend injections of
botulinum toxin (BoNT) as first-line treatment for primary
CD [8]. The efficacy and safety of BoNT in the manage-
ment of CD are well established [9] and several studies
have shown that treatment with BoNT improves quality of
life in CD [10–12]. However, it has been reported that
patient satisfaction can be lower than expected for such an
effective treatment [13, 14] and other studies have shown
that psychosocial factors (e.g., presence of depression,
social support) are also important considerations in patient
management [1, 11–15]. The aim of this international
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online survey was to assess patient views and perceptions
on the impact of their illness and its treatment,
Methods
Survey design
This international online survey was conducted between
March and December 2012. The structure and contents of
the survey were designed in collaboration with Dystonia
Europe and the Dystonia Medical Research Foundation.
The study was supported by Ipsen Pharma.
The survey was designed to be self-report by the patients;
all online survey responses were purely voluntary and as
such no ethics approval was sought. It was first designed in
English, and then translated into French, German and
Spanish; native speakers verified all translations. The survey
was hosted online and included 4 demographic screening
questions and 38 disease-related questions grouped into
categories (‘‘Appendix’’). All of the questions were multiple
choice and 13 included a free entry format as one of the
options. Survey responses were anonymous. The survey was
designed to take approximately 15 min to complete; how-
ever, there was no set time limit for completion.
Survey participants
People with a diagnosis of CD were invited to participate in
the survey by two patient associations: Dystonia Europe
(including their local patient association members) and the
Dystonia Medical Research Foundation, via a social media
campaign. The patient associations hosted links to the
patient survey online, and CD patients were also directed to
the survey through patient society e-mail communications,
newsletters, meetings, and social networking sites (Face-
book and Twitter). Other than having a diagnosis of CD
(self-reported), there were no formal inclusion or exclusion
criteria for participating in this survey.
Data analysis
Descriptive statistics were used to summarize all survey
data collected in this study.
Results
Sample
Over the 10 months that the First International CD Patient
Survey was available online, 1,071 respondents with self-
identified CD completed the survey. Participants were from
five continents (38 countries: Austria, Australia, Belgium,
Brazil, Canada, Croatia, Czech Republic, Denmark, El
Salvador, Finland, France, French Guinea, Germany,
Guyana, Iceland, Ireland, Israel, Italy, Kenya, Mexico,
Netherlands, New Zealand, Norway, Oman, Philippines,
Poland, Portugal, Romania, Russia, Slovak Republic,
Spain, South Africa, Sweden, Switzerland, Taiwan, UK,
USA, Vietnam) The mean (±SD) age of respondents was
53.2 ± 11.9 years and the majority were female (Table 1).
In terms of employment, 42 % of respondents were
employed [full time (24 %), part time (12 %), self-
employed (6 %)], 22 % were retired and 9 % were not
currently employed or were full-time students. Twenty-six
percent responded that they were unable to work/disabled.
Impact of CD on daily living
When asked how the symptoms of CD affected them after
their symptoms first began, two-thirds (66 %) of patients
reported they experienced pain, and 61 % said that they
suffered depression and mood alterations; only 7 % of
respondents reported no impact on their lives (Fig. 1a).
When asked to consider the areas of life most affected
when symptoms were at their worst, a majority of patients
reported a negative impact on general well-being, health
and work/school life (Fig. 1b). Overall, 12 % of patients
reported an effect on ‘other’ life areas, which included
confidence and self-esteem, isolation, sports and exercise.
Table 1 Demographic and clinical characteristics
Characteristic Statistic
Female; n (%) 813 (76)
Age (years); mean ± SD 53.2 ± 11.9
18–24 12 (1 %)
35–44 59 (6 %)
45–54 346 (32 %)
55–64 281 (26 %)
C65 210 (20 %)
Employment status; n (%)
Full time ([30 h/week) 256 (24 %)
Self-employed 62 (6 %)
Full-time student 131 (12 %)
Retired 239 (22 %)
Not able to work/disabled 283 (26 %)
Not currently employed 89 (8 %)
Time since diagnosis (years); mean ± SD 9.6 ± 6.3
Presence of another movement disorder; n (%) 393 (37)
Blepharospasm 84 (8)
Other dystonias (non-specified) 335 (31)
Hemifacial spasm 35 (3)
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Diagnostic issues
Late diagnoses and misdiagnoses were frequently reported
in the survey. Less than half (46 %) of patients were
diagnosed within a year of developing symptoms, 29 %
were diagnosed within 1–5 years, and 25 % of patients
reported that it took at least 5 years for them to receive
their diagnosis. In total, 66 % of patients reported being
misdiagnosed. The most frequent misdiagnoses were:
psychological illness or stress disorder (37 %), cervical
muscle strain (23 %) and tremor (15 %). Overall, 19 % of
patients reported ‘other’ diagnoses, which included Par-
kinson’s disease, essential tremor, multiple sclerosis,
hypochondria, cervical arthritis, scoliosis and whiplash.
After diagnosis, the majority (76 %) of patients looked
for more information on the Internet. Other sources of
information included patient associations (31 %), printed
information at the doctors office (23 %), and primary care
doctor (20 %). Responses were generally consistent across
countries, except in Spain where 69 % consulted a patient
association for more information and only 50 % searched
the Internet.
Fig. 1 Impact of CD on daily life a individual problems b overall
areas of life. Base = 1,071 patients in survey. Patients were asked:
after your first symptoms began a how did they affect and change
your life? b Which of the following areas of life were affected when
your symptoms were at their worst?
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When first discussing CD with their neurologist/move-
ment disorder specialist, only 53 % of patients were sat-
isfied with the information they received about their
condition. The main reasons given for dissatisfaction were:
lack of materials provided (72 %), not enough time with
physician to explain the diagnosis (52 %) and feeling
overwhelmed by the diagnosis (14 %). Of those who
reported dissatisfaction with the information provided
(n = 501), over half said they wanted more time with their
doctor to better understand the diagnosis (n = 259, 52 %).
When these patients were questioned further about how
much time they thought was required to discuss a new
diagnosis, most (52 %) thought that a[ 30 min consulta-
tion was necessary.
Therapeutic relationship and self-management
Despite problems with the diagnosis, almost 70 % of sur-
vey respondents reported being satisfied with the overall
relationship with their doctor. During appointments with
their physicians, 72 % of patients said that they had dis-
cussed treatment expectations. Patient expectations were
high, with 63 % expecting freedom from spasms and 62 %
expecting freedom from pain. Over half (53 %) expected to
be able to return to a normal routine (53 %) (Fig. 2).
With regards to self-management, most patients in the
survey (72 %) had contacted a patient association during
the course of their disease and of these 86 % would rec-
ommend patient societies to other patients. In addition, the
majority of patients (91 %) reported trying practical, self-
managed interventions to improve their condition. The four
most successful interventions were reported as: general rest
(41 %), physiotherapy (28 %), light exercise (25 %) and
massages (23 %). Other interventions deemed successful
included: stress reduction training, Pilates/yoga, gardening,
creative endeavors such as painting or singing, reflexology
and using a foam or water pillow. As a result of these
practical interventions, patients felt an improvement in
symptoms (41 %), mood improvement (35 %) and gained
confidence (27 %), but some patients (32 %) experienced
no change.
Medical treatment of CD
Most patients included in the survey (86 %) had been
treated with BoNT. Other treatments chosen or prescribed
(at any time) included: oral medication (53 %), physio-
therapy (31 %), psychological support (11 %) and surgery/
deep brain stimulation (9 %). Only 21 patients (2 %) did
not receive any treatment. As a result of these medical
intervention(s), most patients (64 %) reported an
improvement in symptoms. Other reported benefits inclu-
ded mood improvement (39 %), gained confidence (31 %),
regained independence (22 %), less anxiety when driving
(21 %) and ability to return to work (17 %). By contrast,
16 % of patients reported that they had not experienced any
improvements. With regards to treatment satisfaction with
their CD treatment, 51 % of patients reported that they
were fairly or completely satisfied, 21 % were neither
satisfied nor dissatisfied, and 28 % reported that they were
Fig. 2 Expectations of treatment following discussion with a doctor.
Base = 772 patients who had discussed expectations regarding
treatment. Patients were asked: after discussing the different treatment
options with your doctor, what were your expectations regarding your
overall treatment plan?
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fairly or completely dissatisfied with their treatment
outcomes.
Of the patients who reported receiving BoNT (n = 907),
the majority of patients (80 %) reported that they had
discussed the potential benefits and side effects of treat-
ment with their doctor. Most (73 %) patients reported an
injection interval of 3 months between treatments, 17 %
reported an interval of 4–6 months, and 2 % reported an
interval of 7–12 months (Fig. 3). In addition, a further 8 %
reported they received their BoNT when required. Since
receiving treatment with BoNT (n = 907); 62 % of
patients reported symptom improvement, 25 % reported no
improvement and 13 % reported a worsening of symptoms.
Considering their BoNT treatment, over half (56 %) of
patients reported that they were completely or fairly sat-
isfied with their treatment, 20 % were neither satisfied nor
dissatisfied, and almost one quarter (24 %) were com-
pletely or fairly dissatisfied (Fig. 3).
When patients who did not report satisfaction with
BoNT treatment (including those who were either satisfied
or dissatisfied; n = 400) were questioned further about
their reasons, 46 % reported that BoNT A did not work for
them and 33 % reported treatment side effects (Fig. 4). In
addition, some patients reported that there was a long
treatment interval (16 %) or that they had difficulty in
attending regular appointments (3 %). When patients who
had difficulty in attending regular appointments (n = 13)
were questioned further about how long their treatments
last, majority of these patients reported that their treatment
lasts for B3 months.
Patients who did not receive treatment with BoNT
(n = 128) cited dislike of toxins (20 %), expense (14 %)
and dislike of injections (8 %) as key reasons for not
having this treatment. In addition, 87 patients (68 %) cited
‘other’ reasons for not receiving BoNT. Although there
was considerable variability in the verbatim texts, the most
common ‘other’ reasons included lack of availability
(many of these patients answered this question in the
context of their first treatments and were now receiving
BoNT), lack of physician awareness and presence of other
dystonias.
Discussion
Health-related quality of life has been defined as ‘‘the gap
between our expectations of health and our experience of
it’’ [16]. To the best of our knowledge, this International
CD Patient Survey is the first and the largest survey
undertaken to collect patient’s own perceptions of their CD
management. In line with previous clinical studies, the
survey found that the signs and symptoms of CD signifi-
cantly impact on several aspects of daily life (including
mood, sleep and pain [4, 17, 18]) and highlight the
importance of managing the full range of problems a
patient with CD might suffer.
Fig. 3 Patient experience with botulinum toxin. Base = 907 patients
who had received treatment with botulinum toxin. Asterisk a total of
77 patients (8 %) reported they received their BoNT injection when
required. Patients were asked: 28. How do you rate the overall
satisfaction of botulinum toxin treatment? Since receiving treatment
with botulinum toxin have your symptoms improved, worsened or
stayed the same? Based on your experience with botulinum toxin
treatment, how long do you have to wait between treatments?
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Late diagnoses and misdiagnoses were a common
complaint in this study. Although there are significant
variations in the reported incidence of CD, one of the most
recent studies conducted in the US reported a minimum
incidence of 1.07 per 100,000 people [19]. This, however,
is thought likely to be an underestimate, as community
prevalence studies show that a significant population of
people with CD do not seek treatment or are misdiagnosed
[20]. Compounding the problem, significant variability in
physicians’ ability to diagnose dystonia has also been
reported, with studies showing that movement disorder
specialists are more able to correctly diagnose CD than
general neurologists [21]. It is hoped that the new definition
and classification system for dystonia will help guide the
diagnosis of this important disorder [22].
The study found that satisfaction with the information
provided at diagnosis was generally low and the majority
of patients used the internet to research their condition.
Studies in neurology clinics indicate that dissatisfaction
with information and emotional support provided by the
physician may be important reasons for patients seeking a
second opinion [23]. Interestingly, receiving a new diag-
nosis and/or treatment advice did not appear to influence
satisfaction in this study. The high percentage of patients
who used the internet to research their condition is likely
due to the methodology used in this study in which patients
were largely recruited through internet sites and social
medial, biasing the study toward those patients with
Internet access and skills.
From this study, patient expectations of treatment were
high with almost two-thirds expecting to be ‘free’ of
spasms or pain. These high expectations may have nega-
tively influenced the satisfaction with overall (any) treat-
ment of CD—whereas 64 % of patients reported symptom
improvements with medical treatment, 49 % of patients
were either equivocal or dissatisfied with their treatment
outcome. This is an important insight, as treatment satis-
faction has been shown to be a key factor in determining
quality of life in CD [24]. The majority (86 %) of the
patients were treated with BoNT therapy and thus the
findings for patient satisfaction with BoNT were similar to
satisfaction with treatment overall. Such findings highlight
the need to explain to patients that while BoNT-A treat-
ment is often effective, it is not a cure and there may be
residual symptoms. Although patient satisfaction with
BoNT treatment has not been found to correlate with the
severity or complexity of CD [14], it is our experience
(especially with more complex patients) that it is worth
discussing that not all types of CD respond in the same way
and there will be variability in how well patients respond to
treatment [25].
It has been suggested that key steps in the management
of CD involve the setting of realistic goals and prioritiza-
tion of these goals with the patient [26]. When patients who
were not satisfied with BoNT treatment (including the
20 % who were neither satisfied or dissatisfied) were
questioned further about their reasons, most patients
responded that BoNT ‘‘did not work’’ for them (46 % of
reasons for non-satisfaction). The wording of this pre-
defined response does not allow us to understand if all
these patients truly had lack of efficacy, or if some other
reason meant it did not work in the way the patients
Fig. 4 Reasons for not being satisfied with botulinum toxin. Base = 400 patients who did not report satisfaction with botulinum toxin treatment.
Patients were asked: why were you not satisfied with your botulinum toxin treatment?
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expected. We do not know in which settings (e.g., expert or
community centers) the patients received treatment, and
lack of efficacy can be due to poor injection technique
(e.g., low doses or inappropriate muscle targeting). It may
also be that the survey included a subgroup of very
severely affected patients who might be candidates for
deep brain stimulation (DBS). Indeed 9 % of patients in
this survey reported previous surgery and or DBS. Other
reasons cited included side effects (33 %), long treatment
intervals or difficulties in attending appointments; the latter
two reasons may be influenced by the healthcare systems of
the respondents’ countries where the minimum interval
between treatments may be different (longer) to the mini-
mum interval of 3 months stipulated in the label of all
BoNT products.
Limitations of this study are those inherent to patient
surveys, which are based on the patient’s own under-
standing of their condition, and are not compared with
objective clinical information (e.g., about disease severity,
or response to treatment). A key limitation was the self-
identification of the respondents as CD patients. There was
no verification of diagnosis other than self-report, and the
survey did not collect information regarding the type of
CD suffered (e.g., predominant pattern or whether the
dystonia was idiopathic, inherited or acquired). Overall,
37 % patients said they were affected by another move-
ment disorder and 31 % patients said they had also had
‘other’ types of dystonia, but no further information on
these important aspects was collected. Another limitation
is the recruitment method in which only those patients
with access and skills in internet use would be likely to
respond to the survey and presumably only a percentage of
patients who were invited to complete the survey through
the media campaign did so. We do not know how many
people received the invitation, and therefore cannot com-
ment on this source of potential bias. Further, the use of
this online tool meant that detailed analyses of answers
was not feasible. Finally, there was an over-representation
of responses from the US (n = 389), while 24 of the 38
individual countries had representation from\10 patients.
In addition, when looking at the ‘other’ reasons for not
having BoNT therapy, a number of patients responded that
there had been a lack of availability of BoNT treatment in
their area, but that they were now receiving it, thereby
indicating that they had misunderstood the time frame of
this question.
Despite the limitations in this type of study, this survey
provided some interesting insights related to self-reported
CD and its management. It highlights that diagnosis of CD
is still delayed despite increasing awareness of the disorder.
It suggests that the patients need to be better informed
about their condition, the treatments available and the
limitations of those treatments. It may be that realistically
managing patient expectations of treatment would reduce
the dissatisfaction of some patients.
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Appendix: International Cervical Dystonia Patient
Survey
Patient demographics
D1. What is your gender?
s Female
s Male





s 55 and older
























s Other, please specify
D4. Which is your current work situation?





s Not able to work/disabled
s Not currently employed
Patient background questions
1. When were you diagnosed with cervical dystonia (also
known as spasmodic torticollis)?
a. Less than a year ago
b. 1–5 years ago
c. 5–10 years ago
d. 10–15 years ago
e. More than 15 years ago
2. If you also have another type of dystonia, which do
you have? [SELECT ALL THAT APPLY]
a. Blepharospasm
b. Hemifacial spasm
c. Other, please specify
d. I do not have another type of dystonia
Change in quality of life
3. After your first symptoms began, how did they affect
and change your life? [SELECT ALL THAT
APPLY]
a. Not able to work anymore
b. Loss of independence in everyday life activities
(not able to drive, personal care)
c. Relationships with family members suffered
d. Not able to go shopping
e. No leisure activities (restaurants, theatres)
f. Depression and mood alterations
g. Experienced a lot of pain
h. Lack of sleep
i. Increase in alcohol intake
j. No effects or changes
4. After your first symptoms began, which of the
following areas of life were affected when your








g. Other, please specify
h. No effect on relationships
Unmet needs—patients without confirmed diagnosis
and treatment started
5. After your first symptoms began, when were you
diagnosed with cervical dystonia?
a. 0–6 months later
b. 6–12 months later
c. More than 1 year later
d. More than 5 years later
6. Before your diagnosis of cervical dystonia, were you
misdiagnosed with any of the following related
neurological movement disorders? [SELECT ALL
THAT APPLY]







h. Psychological illness/stress-related disorder
i. Others, please specify
j. No, I was never misdiagnosed
7. After you were diagnosed with cervical dystonia,
where did you look for more information about your
condition? [SELECT ALL THAT APPLY]
a. Internet
b. Patient association
c. Printed information in the doctor’s office
d. From general practitioner/family practice doctor
e. Other, please specify
f. Did not search for more information
Patient’s expectations regarding relationship with
doctors
8. When you first talked to your neurologist/movement
disorder specialist were you satisfied with the infor-
mation you received about your condition?
a. Yes
b. No
9. IF Q8=B, why were you NOT satisfied with the
information you received about your condition?
[SELECT ALL THAT APPLY]
a. Not provided with enough information
844 J Neurol (2015) 262:837–848
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b. My doctor used too many technical words
c. My doctor did not spend enough time to explain
the diagnosis
d. I felt overwhelmed with information
e. Problems with communication due to language/
dialect issues
f. Other, please specify
10. IF Q9=C, how much time with your neurologist/
movement disorder specialist did you think was
required when first discussing your diagnosis?
a. 20–30 minutes
b. 30–40 minutes
c. More than 40 minutes
11. Were you satisfied with the overall relationship you




12. If Q11=B,C why were you not completely satisfied
with the overall relationship you had with your doctor?
Overall Approach to treatment of Dystonia
13. Did you discuss your expectations regarding treat-
ment with your doctor?
a. Yes
b. No
14. If Q13=A, after discussing the different treatment
options with your doctor, what were your expecta-
tions regarding your overall treatment plan?
[SELECT ALL THAT APPLY]
a. To be free of spasms
b. To be free of pain
c. To feel well overall
d. To feel confident
e. To be able to work
f. To be able to sleep better
g. To be able to drive
h. To be able to have fun, enjoyment (leisure)
i. To return to normal routine before my symp-
toms began
15. If you were given support materials to read about
cervical dystonia when you were diagnosed by your
doctor or nurse, what were you given? [SELECT
ALL THAT APPLY]
a. Leaflets and brochures
b. Patient organisations to contact
c. Support group information
d. Doctor found information on computer
e. Did not receive any support materials
16. What best describes your current healthcare
finances? [SELECT MOST SUITABLE OPTION]
a. Government funded/government program
b. Private healthcare insurance
c. Combination of personal and government
funded/government program
d. Public healthcare plan
e. Self-funded




Practical treatments of Dystonia
18. When you were diagnosed with cervical dystonia,
which, if any, of the following practical improve-
ments did you try? [SELECT ALL THAT
APPLY]?
a. Using a foam/water pillow
b. Using a water bed
c. Massages (shiatsu, etc.)
d. Reflexology
e. Pilates/Tai Chi/Yoga
f. Creative or artistic activities (painting, sing-
ing, music therapy)
g. Gardening
h. Stress reduction training
i. Light exercise (walking, swimming, dancing)
j. Physiotherapy/physical therapist
k. General rest
l. None of these
19. Which, if any, of the following practical suggestions
helped reduce your symptoms? [SELECT ALL
THAT APPLY]?
a. Using a foam/water pillow
b. Using a water bed
c. Massages (shiatsu, etc.)
d. Reflexology
e. Pilates/Tai Chi/Yoga
f. Creative or artistic activities (painting, sing-
ing, music therapy)
g. Gardening
h. Stress reduction training
i. Light exercise (walking, swimming, dancing)
j. Physiotherapy/physical therapist
k. General rest
J Neurol (2015) 262:837–848 845
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l. None of these
20. As a result of your practical improvements, which of
the following areas did you feel most benefit?
[SELECT ALL THAT APPLY]
a. Regained independence
b. Gained confidence
c. Able to play sports
d. Mood improvement
e. Able to go back to work
f. Less anxious driving
g. Developed new skills
h. Changes in relationships
i. Improvement of my symptoms
j. Other, please specify
k. No changes
Medical Treatments of Dystonia
21. Which treatment options did your doctor suggest to help
your condition? [SELECT ALL THAT APPLY]
a. Oral medication
b. Botulinum toxin injections
c. Physiotherapy/physical therapist
d. Surgery/deep brain stimulation
e. Psychological support/counselling support
f. Other, please specify
g. None of these
22. Which treatment option did you choose or did your
doctor prescribe? [SELECT ALL THAT APPLY]
a. Oral medication
b. Botulinum toxin injections
c. Physiotherapy/physical therapist
d. Surgery/deep brain stimulation
e. Psychological support/counselling support
f. Other
23. As a result of the treatment option you chose or was
prescribed by your doctor, which of the following




c. Able to play sports
d. Mood improvement
e. Able to go back to work
f. Less anxious driving
g. Developed new skills
h. Changes in relationships
i. Improvement of my symptoms
j. Other, please specify
k. No changes




c. Neither satisfied nor dissatisfied
d. Fairly dissatisfied
e. Completely dissatisfied
Patient’s expectations of Botulinum Toxin (BoNT A)
Questions 25–30 are for respondents who selected
option B in Q21
25. Did you discuss the benefits and side effects of
botulinum toxin with your doctor?
a. Yes
b. No
c. Not enough, please specify
26. Since receiving treatment with botulinum toxin have
your symptoms:
a. Improved
b. Stayed the same
c. Worsened
27. Based on your experience with botulinum toxin




c. 6 months to 1 year
d. Receive my botulinum toxin treatment when I
need it




c. Neither satisfied nor dissatisfied
d. Fairly dissatisfied
e. Completely dissatisfied
29. If Q28 = C,D,E, why were you not satisfied with
your botulinum toxin treatment? [SELECT ALL
THAT APPLY]
a. It did not work for me
b. Treatment side effects
c. Too expensive
d. Treatment interval is too long
e. Too difficult to attend regular treatment
f. Other, please specify
30. If Q29 = D, how long do the effects of your
botulinum toxin treatment last?







f. Over 6 months
31. If Q22 = C, was it helpful to visit a physiotherapist
who specialises in dystonia?
a. Yes
b. No
c. Did not visit a physiotherapist who specialises
in dystonia
32. If Q22 = A,D,E,F, for what reason(s) were you not
prescribed botulinum toxin treatment? [SELECT
ALL THAT APPLY]
a. Have a contraindication (e.g. pregnancy, allergy
of botulinum toxin components etc.)
b. Inconvenience/trouble of returning for treatment
c. Do not like the idea of putting toxins into my
body
d. Do not like injections
e. Too expensive
f. Other, please specify
Personal experiences regarding patient care for
dystonia
33. Since you were diagnosed with cervical dystonia, did
you contact a patient organisation or support group?
a. Yes
b. No
34. If Q33 = A, how did you receive the details of the
patient organisation or support group? [CHOOSE
ONE]
a. Through the physician
b. Through the nurse
c. Leaflet/poster information in the hospital
d. Internet (search engine)
e. Social media (facebook, twitter)
35. If Q33 = A, if you joined a dystonia patient
organisation or support group, would you recom-




c. I didn’t join a patient group or society
36. If Q35 = B, why would you NOT recommend the
patient organisation or support group you joined?
[SELECT ALL THAT APPLY]
a. They do not offer the help I need
b. The group is not interactive
c. They do not provide enough educational
materials/information about my condition
d. Other, please specify




38. If Q37 = A, how were you asked to provide this
feedback?
a. Arrange another appointment
b. Write or email the doctor
c. Other, please specify
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